Log in

NASDAQ:FLXNFlexion Therapeutics Stock Price, Forecast & News

$11.99
-0.17 (-1.40 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.88
Now: $11.99
$12.21
50-Day Range
$9.69
MA: $12.00
$13.26
52-Week Range
$5.01
Now: $11.99
$22.98
Volume315,819 shs
Average Volume844,334 shs
Market Capitalization$462.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Read More
Flexion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.6Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$72.96 million
Book Value($0.53) per share

Profitability

Net Income$-149,770,000.00
Net Margins-175.76%

Miscellaneous

Employees288
Market Cap$462.37 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

How has Flexion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FLXN shares have decreased by 2.6% and is now trading at $11.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Flexion Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Flexion Therapeutics.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Flexion Therapeutics.

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) released its quarterly earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported ($0.95) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.00) by $0.05. The specialty pharmaceutical company earned $20.13 million during the quarter, compared to the consensus estimate of $18.45 million. Flexion Therapeutics had a negative net margin of 175.76% and a negative return on equity of 592.50%. View Flexion Therapeutics' earnings history.

What price target have analysts set for FLXN?

10 brokers have issued 1-year price objectives for Flexion Therapeutics' shares. Their forecasts range from $17.00 to $35.00. On average, they expect Flexion Therapeutics' share price to reach $23.50 in the next twelve months. This suggests a possible upside of 96.0% from the stock's current price. View analysts' price targets for Flexion Therapeutics.

Has Flexion Therapeutics been receiving favorable news coverage?

News articles about FLXN stock have been trending somewhat negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Flexion Therapeutics earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Flexion Therapeutics.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Cara Therapeutics (CARA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Inovio Pharmaceuticals (INO), Micron Technology (MU) and NVIDIA (NVDA).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 68, Pay $1.06M)
  • Dr. Neil Bodick, Consultant (Age 73, Pay $657.6k)
  • Dr. Scott D. Kelley, Chief Medical Officer (Age 61, Pay $626.53k)
  • Mr. David A. Arkowitz, Chief Financial Officer (Age 59)
  • Scott Young, VP of Corp. Communications & Investor Relations

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Moody National Bank Trust Division (1.00%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Michael D Clayman and Samuel D Colella. View institutional ownership trends for Flexion Therapeutics.

Which institutional investors are buying Flexion Therapeutics stock?

FLXN stock was bought by a variety of institutional investors in the last quarter, including Moody National Bank Trust Division. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Mark Stejbach, Michael D Clayman, and Samuel D Colella. View insider buying and selling activity for Flexion Therapeutics.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $11.99.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $462.37 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 288 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.